公司概述
Akanda Corp. operates within the healthcare sector, specifically functioning as a drug manufacturer specializing in specialty and generic pharmaceuticals, although its current operational focus involves the cultivation, manufacture, and distribution of cannabis-based products through its subsidiaries. The company was incorporated in 2021 and is headquartered in an undisclosed location, having recently undergone a significant corporate restructuring as of August 21, 2025, when it was acquired by First Towers & Fiber Corp. in a reverse merger transaction. As of the latest data, the company's market capitalization stands at $1.59 million, while its trailing twelve-month revenue is reported at $836,664. With employee data listed as N/A, the firm currently operates on a micro-cap scale, indicated by a valuation that is substantially below one billion dollars. This small market cap and limited revenue figure suggest that Akanda Corp. remains a nascent or transitional entity within the broader healthcare landscape, likely facing the challenges of scaling operations or transitioning its business model following the reverse merger.
财务健康
The company reported a revenue of $836,664 over the trailing twelve months, yet it simultaneously posted a net income of -$2,395,394 and an EBITDA of -$3,678,018. The substantial gap between the modest revenue of $836,664 and the significant net loss of $2,395,394 reveals a cost structure where operating expenses and non-operating costs vastly exceed total sales, a common characteristic in early-stage biotech or cannabis companies but indicative of current financial distress for Akanda Corp. Free cash flow for the period was -$4,874,154, which indicates that the company is burning cash at a rate that exceeds its operational cash generation, thereby limiting its financial flexibility and reliance on external capital sources. Profitability metrics further reflect this struggle, with a gross margin of 24.9% showing that the company retains a portion of revenue after cost of goods sold, while an operating margin of -443.8% and a profit margin of -266.3% demonstrate that operating expenses are more than four times the revenue and total losses exceed sales volume. The balance sheet shows a cash position of $2.52 million against total debt of $391,241, resulting in a debt-to-equity ratio of 11.85, which suggests a highly leveraged financial structure where equity capital is minimal relative to debt obligations. Despite the high leverage, the current ratio stands at 1.25, indicating that the company possesses sufficient current assets to cover its short-term liabilities, though the margin for error is narrow given the negative cash flow. Return on equity is -60.9% and return on assets is -28.7%, revealing that management has not yet generated positive returns on the capital invested by shareholders or utilized in the asset base, reflecting the ongoing nature of the company's operational losses.
估值评估
Akanda Corp. presents a trailing P/E ratio of 0.00 due to its negative earnings, while the forward P/E is listed as N/A, implying that the market cannot currently value the stock based on expected future earnings multiples. The price-to-book ratio is 0.03, which indicates that the market values the company at a fraction of its book value, suggesting that investors are pricing in significant risks or expecting substantial future impairment of assets. Alternative valuation metrics include a price-to-sales ratio of 1.91 and an EV/EBITDA of 0.55, which suggest that the stock is priced relative to its revenue and enterprise value despite the lack of positive earnings. The stock has traded between a 52-week high of $46.45 and a 52-week low of $0.51; given the market cap of $1.59 million and the historical volatility, the current price sits significantly below the 52-week high, reflecting a correction from earlier peaks. The beta of 1.73 indicates that the stock price is 73% more volatile than the broader market, meaning that price movements will likely be amplified relative to general market swings, adding to the risk profile of holding this small-cap healthcare stock.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue at this specific point in time. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are theoretically available for reinvestment, though currently, the company is absorbing losses rather than distributing income. Since the company is not a dividend payer, the strategy involves reinvesting any potential future earnings or utilizing cash reserves to fund growth initiatives, research, or operational expansion within the cannabis and drug manufacturing sectors. The overall growth and income profile for Akanda Corp. is currently defined by zero dividend income and undefined growth rates, placing the entire investment thesis on the potential for future operational turnaround or successful integration post-acquisition rather than current financial performance or income generation.